Non-coding RNAs as emerging biomarkers in melanoma

Melanoma remains one of the most aggressive forms of skin cancer, with an increasing incidence and limited therapeutic success in advanced stages. Early detection and precise prognostic assessment are critical for improving patient outcomes, yet conventional biomarkers often lack sensitivity and specificity. In recent years, noncoding RNAs (ncRNAs), including microRNAs, long noncoding RNAs, and circular RNAs, have emerged as pivotal regulators of melanoma biology. These molecules modulate key pathways involved in tumor initiation, progression, metastasis, and therapeutic resistance while also demonstrating remarkable stability in biofluids, making them attractive candidates for minimally invasive diagnostics. This narrative review synthesizes current evidence on the role of ncRNAs as emerging biomarkers in melanoma, highlighting their potential utility in early detection, prognostic stratification, and prediction of therapeutic response. Furthermore, we discuss methodological advances in ncRNA profiling, translational challenges, and future directions for integrating ncRNA-based assays into clinical practice. By consolidating mechanistic insights and clinical relevance, this review underscores the promise of ncRNAs as transformative tools in precision oncology for melanoma management.